At the news
? NEUTRALIMPACT 2/10 DEFA14A filed Apr 21, 2026 at 16:07 ET
Arcus Biosciences, Inc. is holding its 2026 Annual Meeting to vote on director elections, auditor appointment ratification, and executive compensation. This is a routine proxy filing, not a shareholder vote outcome. A recent officer departure filing suggests potential governance issues, but the proxy itself is standard.
- Filing is a DEFA14A, the definitive proxy statement for the 2026 Annual Meeting.
- Vote items include the election of four directors, ratification of Ernst & Young as auditors, and advisory approval of executive compensation.
- A recent 8-K filing (March 23, 2026) reported the departure of an officer, which may indicate internal changes.
- The filing is routine and does not contain material financial information or significant strategic announcements.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access